Reports and Papers
PEOPLE’S VACCINE ALLIANCE COMMENTS ON THE ZERO DRAFT OF THE WHO CA+
First published: 14 February 2023
STUDY ON THE AVAILABILITY AND AFFORDABILITY OF DIAGNOSTICS FOR COVID-19 AND MPOX IN LOW AND MIDDLE-INCOME COUNTRIES
First published: 31 January 2023
Commissioned by the PVA and written by Dr Fifa Rahman of Matahari Global Solutions, this report seeks to analyse availability and accessibility of diagnostics for COVID-19 and MPOX in anticipation of discussions on an expansion of the TRIPS waiver and with the objective of understanding barriers to people in LMICs accessing diagnostics considering regulatory mechanisms, supply chain barriers, as well as any policy barriers that prevent people in LMICs being able to access diagnostics when they needed it.
A FACT-BASED CASE FOR THE EXTENSION OF THE TRIPS COVID DECISION
First published: 15 November 2022
A technical briefing calling on the member states of the World Trade Organisation (WTO) to support the extension of the WTO ministerial decision, agreed on 17 June 2022 to COVID-19 therapeutics and diagnostics, to enable diversified manufacturing and supply and to close the access gap facing people in low- and middle-income countries.
BERLIN DECLARATION: KEY CLAIMS AND CRITIQUES
First published: 18 October 2022
Commissioned by the People’s Vaccine Alliance Policy & Advocacy Working Group and written by Lauren Paremoer in October 2022.
A comprehensive rebuttal by the People’s Vaccine Alliance of a lobbying document from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), titled the Berlin Declaration.
Key Issues and Recommendations for the International Treaty on Pandemic Prevention, Preparedness, Response and Recovery
First published: 11 October 2022
Written by Mohga Kamal-Yanni with input from Piotr Kolczyński, Anna Marriott and members of the People’s Vaccine Alliance Policy Group in September 2022.
Key recommendations from the People’s Vaccine Alliance on how the world can prevent and prepare for future health crises, and respond and recover should they happen.
Policy Brief: Third-Way Proposals from Big Pharma and the WTO are the Same-Old Way –
Commercial Control of Supply, Price, and Distribution
First published: April 2021
Written by Professor Brook K. Baker, Senior Health GAP Policy Analyst.
PVA Supported Reports
“ONE-SIDED” – THE BIG PHARMA BULLIES: Secrecy for Vaccine Suppliers in a Pandemic
First published: 5 September 2023
Produced by Health Justice Initiative and a multi-stakeholder group including Alliance members, an analysis of the South African COVID-19 vaccine procurement contracts. Analysis of these Contracts/Agreements, which were not previously available to the public reveal that the terms and conditions are overwhelmingly one-sided and favour multinational corporations, placing the South African government in the position of having to secure scarce supplies in a global emergency with unusually hefty demands and conditions, including secrecy, a lack of transparency, and very little leverage against late or no delivery of supplies or inflated prices. For more on this, and to read the contracts, see here.
MAKE POOLING WORK TO END PANDEMICS: A QUALITATIVE ANALYSIS OF THE COVID-19 TECHNOLOGY ACCESS POOL
First published: 9 November 2022
Commissioned by Wemos with support of People’s Vaccine Alliance and written by Julia Hochberger. This report shows that lack of resources, political support and unwillingness of pharmaceutical companies caused the limited success of the Covid-19 Technology Access Pool (C-TAP) of the World Health Organization (WHO). This mechanism for global pooling of intellectual property (IP), knowledge and data for the production of medical products, could have had a big impact in curbing the pandemic, but so far it has received insufficient support from governments, pharmaceutical companies and the WHO itself. To curb Covid-19 and future pandemics, such a mechanism requires greater commitment and decisiveness. The report provides recommendations for its future improved functioning.